一品红(300723.SZ)子公司获得注射用硫酸艾沙康唑注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, marking a significant step in enhancing its product pipeline and competitiveness in the anti-infection sector [1] Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Sulfate Isavuconazole [1] - The approved indication for injectable Sulfate Isavuconazole is primarily for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis [1] - This approval allows the company to sell this specific drug in the domestic market, thereby enriching its product offerings [1]